Could an arthritis drug help fight tough breast cancers?
NCT ID NCT05846789
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether adding tocilizumab, an anti-inflammatory drug, to standard chemotherapy improves outcomes for people with metastatic triple-negative or ER-low breast cancer. Researchers will compare the combination to chemotherapy alone in 168 Black and non-Black patients. The goal is to see if the drug shrinks tumors and slows cancer growth, while also exploring differences in inflammation between racial groups.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tocilizumab (a drug that blocks inflammation) combined with standard chemotherapy
What this could lead to
If it works, this could point toward a more effective treatment for hard-to-treat breast cancers, especially by reducing inflammation that may help tumors grow.
What could go wrong
This is an early phase II trial with only 168 participants, so results may not apply to everyone. Tocilizumab can increase infection risk, and the added benefit over chemo alone is uncertain.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Duke University
RECRUITINGDurham, North Carolina, 27708, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Emory University
RECRUITINGAtlanta, Georgia, 30322, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
IU Health Joe and Shelly Schwarz Cancer Center
RECRUITINGCarmel, Indiana, 46032, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
RECRUITINGIndianapolis, Indiana, 46202, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Roswell Park Comprehensive Cancer Center
RECRUITINGBuffalo, New York, 14203, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Sidney and Lois Eskenazi Hospital
RECRUITINGIndianapolis, Indiana, 46202, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••